Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development Overview
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEW
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEW
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEW
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWExplore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSAn in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTS
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MORE
"At IQVIA your potential has no limits. We thrive on bold ideas and fearless innovation. Join us in reimagining what’s possible.
VIEW ROLESBiosimilar use is growing globally with more physicians becoming experienced and comfortable with their use. These biosimilars have also provided substantial savings for the overall healthcare system.
In 2023, IQVIA Institute published a report highlighting the importance of physician perspectives on biosimilars for their optimal utilization. This viewpoint continues to remain important and relevant, particularly as biosimilars enter new disease areas, including ones which involve complex interactions with a broad set of healthcare professionals. In such cases, different physician groups within a disease area may have varied experience with biosimilars. Ensuring that all groups are comfortable with and have knowledge about biosimilars is crucial to continue to gain the benefits from these biosimilars.
This report presents a case study of Osteoporosis which expects to see the entry of biosimilars in 2025. Osteoporosis has a complex patient pathway which involves several healthcare professionals and different stages. Additionally, the patient pathway and the specialists involved can vary substantially across countries and disease stages in Europe. The degree of familiarity and prior experience with biosimilars is likely to be highly variable across physician groups with some groups having never prescribed biosimilars.
This report provides the results of a survey of several physicians that are involved in the treatment and management of osteoporosis. The survey aims to understand the current state of knowledge about biosimilars across physician groups and potential barriers to optimal biosimilar use from a physician perspective.
The report utilizes the survey findings to highlight some possible solutions to overcome challenges regarding the variable level of knowledge and experience with biosimilars.
Biosimilars generate savings for the healthcare system and can expand access to biologics. As of July 2024, the cumulative savings at list prices from the impact of biosimilar competition in Europe reached €56 Bn. Ensuring a healthy level of competition and overall sustainability in the biologics market is important for achieving these benefits.
Analyze industry leading sales and medical data in a standardized and comparable way, including cross-country analysis of performance and additional insights into global and regional markets.
Bring your biosimilar to market faster by tapping into unparalleled data, technology, advanced analytics, and scientific expertise.
Patients with rheumatic disease often deal with chronic conditions impacting daily activities. The need for new therapies is high. Each clinical trial brings hope of effective disease management. Our experienced rheumatology team is here to support.
